Heat Biologics: Rises after update on lung cancer drug trial

Scorpius Holdings

28/03/2019 13:14

** Shares of cancer drug developer  HTBX.O  up 7.4 pct at
$1.30 premarket
    ** Co says on track to complete enrollment of mid-stage lung
cancer trial in Q2  urn:newsml:reuters.com:*:nACS2br9da
    ** Also says additional $6.9 mln in grant funds expected in
Q2 
    ** "We believe we are well-funded beyond completion of our
mid-stage trial of cancer drug HS-110" - CEO 
    ** Up to Wednesday's close, stock had fallen 33.9 pct over
past 12 months

 (Reporting by Tamara Mathias in Bengaluru)
 ((Tamara.Mathias@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 1208; Reuters Messaging:
tamara.mathias.thomsonreuters.com@reuters.net))